{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:28:49Z","timestamp":1791167329694,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2899,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.exphem.2014.03.005","type":"journal-article","created":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T11:00:11Z","timestamp":1396436411000},"page":"516-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in\u00a0vitro"],"prefix":"10.1016","volume":"42","author":[{"given":"Arnold","family":"Bolomsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schreder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Mei\u00dfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Zojer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2014.03.005_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2014.03.005_bib2","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","article-title":"Advances in the biology and treatment of bone disease in multiple myeloma","volume":"17","author":"Raje","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2014.03.005_bib3","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2014.03.005_bib4","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.005_bib5","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.005_bib6","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/bcj.2011.22","article-title":"Myeloma cells suppress osteoblasts through sclerostin secretion","volume":"1","author":"Colucci","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2014.03.005_bib7","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.exphem.2014.03.005_bib8","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2014.03.005_bib9","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2006-07-034884","article-title":"HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma","volume":"109","author":"Standal","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.005_bib10","doi-asserted-by":"crossref","first-page":"e9870","DOI":"10.1371\/journal.pone.0009870","article-title":"TGF-\u03b2 inhibition restores terminal osteoblast differentiation to suppress myeloma growth","volume":"5","author":"Takeuchi","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.exphem.2014.03.005_bib11","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1158\/0008-5472.CAN-12-2664","article-title":"p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction","volume":"72","author":"He","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2014.03.005_bib12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2214\/ajr.160.5.8470575","article-title":"MR appearance of multiple myeloma of the spine before and after treatment","volume":"160","author":"Rahmouni","year":"1993","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.exphem.2014.03.005_bib13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1634\/theoncologist.2010-0225","article-title":"The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future","volume":"16","author":"Pozzi","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.exphem.2014.03.005_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in\u00a0vitro and in\u00a0vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.005_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.leukres.2009.07.017","article-title":"Constitutive down-regulation of Osterix in osteoblasts from myeloma patients. In\u00a0vitro effect of Bortezomib and Lenalidomide","volume":"34","author":"De Matteo","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2014.03.005_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bone in\u00a0vivo","volume":"84","author":"Pennisi","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2014.03.005_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2014.03.005_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/156800910791054239","article-title":"Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function","volume":"10","author":"Ghandi","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.exphem.2014.03.005_bib19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2009-05-221077","article-title":"Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia","volume":"115","author":"Pal","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.005_bib20","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2014.03.005_bib21","first-page":"129","article-title":"Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation","volume":"33","author":"Munemasa","year":"2008","journal-title":"Int J Oncol"},{"key":"10.1016\/j.exphem.2014.03.005_bib22","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/leu.2013.50","article-title":"Lenalidomide in combination with an activin-A neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy","volume":"27","author":"Scullen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2014.03.005_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2008-10-184226","article-title":"Induction of angiogenesis by normal and malignant plasma cells","volume":"114","author":"Hose","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.005_bib24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nbt0604-656b","article-title":"Preprocessing of oligonucleotide array data","volume":"22","author":"Wu","year":"2004","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2014.03.005_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using Empirical Bayes methods","volume":"8","author":"Johnson","year":"2007","journal-title":"Biostatistics"},{"key":"10.1016\/j.exphem.2014.03.005_bib26","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"key":"10.1016\/j.exphem.2014.03.005_bib27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery: a practical and powerful approach to multiple testig","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B"},{"key":"10.1016\/j.exphem.2014.03.005_bib28","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor open software development for computational biology and bioinformatics","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol"},{"key":"10.1016\/j.exphem.2014.03.005_bib29","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis","volume":"47","author":"Chen","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.exphem.2014.03.005_bib30","first-page":"204","article-title":"Re-emergence of thalidomide","volume":"35","author":"Patil","year":"2003","journal-title":"Indian Journal of Pharmacology"},{"key":"10.1016\/j.exphem.2014.03.005_bib31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0609.2010.01485.x","article-title":"First line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in\u00a0vitro","volume":"85","author":"Lund","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2014.03.005_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3816\/CLM.2006.n.047","article-title":"Response to bortezomib and activtivation of osteoblasts in multiple myeloma","volume":"7","author":"Zangari","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.exphem.2014.03.005_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2520.x","article-title":"First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma","volume":"76","author":"Tosi","year":"2006","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.exphem.2014.03.005_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ajh.23577","article-title":"The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed\/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group","volume":"89","author":"Terpos","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2014.03.005_bib35","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","article-title":"Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy","volume":"23","author":"Terpos","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2014.03.005_bib36","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/leu.2008.235","article-title":"The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed\/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis","volume":"22","author":"Terpos","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2014.03.005_bib37","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1182\/blood-2006-11-056747","article-title":"The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells","volume":"109","author":"Colla","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.005_bib38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbrc.2010.02.171","article-title":"Sp7\/Osterix up-regulates the mouse pro-alpha3(V) collagen gene (Col5a3) during the osteoblastic differentiation","volume":"394","author":"Yun-Feng","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2014.03.005_bib39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1359\/jbmr.091106","article-title":"Role of chemerin\/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stromal cells","volume":"25","author":"Muruganandan","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.exphem.2014.03.005_bib40","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1007\/s11033-010-0665-2","article-title":"Replicative senescence of human bone marrow and umbilical cord derived mesenchymal stem cells and their differentiation to adipocytes and osteoblasts","volume":"38","author":"Cheng","year":"2011","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.exphem.2014.03.005_bib41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.cyto.2011.10.023","article-title":"Glial cell line-derived neurotrophic factor influences proliferation of osteoblastic cells","volume":"57","author":"Gale","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.exphem.2014.03.005_bib42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5051\/jpis.2011.41.1.30","article-title":"Analysis of gene expression during mineralization of cultured human periodontal ligament cells","volume":"41","author":"Choi","year":"2011","journal-title":"J Periodontal Implant Sci"},{"key":"10.1016\/j.exphem.2014.03.005_bib43","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00198-011-1728-5","article-title":"Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells","volume":"23","author":"Baniwal","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.exphem.2014.03.005_bib44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-010-0848-5","article-title":"Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis","volume":"125","author":"Pollari","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.exphem.2014.03.005_bib45","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/jbmr.269","article-title":"Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells","volume":"26","author":"Schulze","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.exphem.2014.03.005_bib46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrm3254","article-title":"Building strong bones: molecular regulation of the osteoblast lineage","volume":"13","author":"Long","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.exphem.2014.03.005_bib47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2006-08-042374","article-title":"Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth","volume":"110","author":"Chen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.005_bib48","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2008-02-133751","article-title":"Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular cells: a novel mechanism of tumor-induced vasculogenesis","volume":"113","author":"Chen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.03.005_bib49","doi-asserted-by":"crossref","first-page":"e33179","DOI":"10.1371\/journal.pone.0033179","article-title":"Bone turnover in wild type and pleiotrophin-transgenic mice housed for three months in the International Space Station (ISS)","volume":"7","author":"Travella","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2014.03.005_bib50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bone.2009.09.015","article-title":"A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts","volume":"46","author":"Trost","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.exphem.2014.03.005_bib51","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/(SICI)1097-4644(19960401)61:1<152::AID-JCB16>3.0.CO;2-Q","article-title":"Acidic fibroblast growth factor inhibits osteoblast differentiation in\u00a0vitro: altered expression of collagenase, cell growth-related, and mineralization-associated genes","volume":"61","author":"Tang","year":"1996","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.exphem.2014.03.005_bib52","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1210\/en.2004-0766","article-title":"Skeletal overexpression of gremlin impairs bone formation and causes osteopenia","volume":"146","author":"Gazzero","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.exphem.2014.03.005_bib53","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/jcp.23010","article-title":"The transcription factor osterix (SP7) regulates BMP6-induced human osteoblast differentiation","volume":"227","author":"Zhu","year":"2012","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.exphem.2014.03.005_bib54","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s00223-008-9138-1","article-title":"Osteoadherin is upregulated by mature osteoblasts and enhances their in\u00a0vitro differentiation and mineralization","volume":"82","author":"Rehn","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.exphem.2014.03.005_bib55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1042\/BJ20090542","article-title":"Asporin competes with decorin for collagen binding, binds calcium and promotes osteoblast collagen mineralization","volume":"423","author":"Kalamajski","year":"2009","journal-title":"Biochem J"},{"key":"10.1016\/j.exphem.2014.03.005_bib56","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.exphem.2014.03.005_bib57","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14001350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14001350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:31:48Z","timestamp":1759566708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X14001350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0301472X14001350"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2014.03.005","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in\u00a0vitro","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2014.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}